Viridian Therapeutics, Inc.\DE Net Cash Provided by (Used in) Financing Activities in USD from 2013 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Viridian Therapeutics, Inc.\DE quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2013 to Q1 2025.
  • Viridian Therapeutics, Inc.\DE Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $9.21M, a 94.8% decline year-over-year.
  • Viridian Therapeutics, Inc.\DE annual Net Cash Provided by (Used in) Financing Activities for 2024 was $458M, a 103% increase from 2023.
  • Viridian Therapeutics, Inc.\DE annual Net Cash Provided by (Used in) Financing Activities for 2023 was $226M, a 30% decline from 2022.
  • Viridian Therapeutics, Inc.\DE annual Net Cash Provided by (Used in) Financing Activities for 2022 was $322M, a 157% increase from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Viridian Therapeutics, Inc.\DE Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $9.21M -$168M -94.8% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q1 2024 $177M +$169M +2058% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q1 2023 $8.2M +$7.47M +1012% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 $738K -$521K -41.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q1 2021 $1.26M -$16.5M -92.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q1 2020 $17.7M +$17.5M +8026% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q1 2019 $218K -$37.9M -99.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q1 2018 $38.1M -$1M -2.56% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q1 2017 $39.1M +$39.1M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q1 2016 $0 -$9.3M -100% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q1 2015 $9.3M +$9.49M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
Q1 2014 -$189K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-15

Viridian Therapeutics, Inc.\DE Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $458M +$232M +103% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-03
2023 $226M -$96.6M -30% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-03
2022 $322M +$197M +157% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-03
2021 $125M +$24M +23.7% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $101M +$101M +144630% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-11
2019 $70K -$41.8M -99.8% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-26
2018 $41.9M -$10.6M -20.1% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-13
2017 $52.5M +$36.6M +231% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-14
2016 $15.9M +$3.17M +24.9% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-15
2015 $12.7M +$5.31M +71.8% Jan 1, 2015 Dec 31, 2015 10-K 2017-03-24
2014 $7.4M +$6.14M +488% Jan 1, 2014 Dec 31, 2014 10-K 2016-03-21
2013 $1.26M Jan 1, 2013 Dec 31, 2013 10-K 2015-03-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.